154 related articles for article (PubMed ID: 36378539)
21. SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.
Guo L; Wang G; Wang Y; Zhang Q; Ren L; Gu X; Huang T; Zhong J; Wang Y; Wang X; Huang L; Xu L; Wang C; Chen L; Xiao X; Peng Y; Knight JC; Dong T; Cao B; Wang J
Lancet Microbe; 2022 May; 3(5):e348-e356. PubMed ID: 35345417
[TBL] [Abstract][Full Text] [Related]
22. SARS-CoV-2 Neutralizing Monoclonal Antibodies for the Treatment of COVID-19 in Kidney Transplant Recipients.
Wang AX; Busque S; Kuo J; Singh U; Röeltgen K; Pinsky BA; Chertow GM; Scandling JD; Lenihan CR
Kidney360; 2022 Jan; 3(1):133-143. PubMed ID: 35368573
[TBL] [Abstract][Full Text] [Related]
23. SARS-CoV-2 monoclonal antibody treatment followed by vaccination shifts human memory B cell epitope recognition suggesting antibody feedback.
Coelho CH; Bloom N; Ramirez SI; Parikh UM; Heaps A; Sieg SF; Greninger A; Ritz J; Moser C; Eron JJ; Currier JS; Klekotka P; Wohl DA; Daar ES; Li J; Hughes MD; Chew KW; Smith DM; Crotty S;
bioRxiv; 2023 Nov; ():. PubMed ID: 38045374
[TBL] [Abstract][Full Text] [Related]
24. Effect of monoclonal antibody therapy on the endogenous SARS-CoV-2 antibody response.
Kim PS; Dimcheff DE; Siler A; Schildhouse RJ; Chensue SW
Clin Immunol; 2022 Mar; 236():108959. PubMed ID: 35218964
[TBL] [Abstract][Full Text] [Related]
25. Spike-specific T-cell responses in patients with COVID-19 successfully treated with neutralizing monoclonal antibodies against SARS-CoV-2.
Rotundo S; Vecchio E; Abatino A; Giordano C; Mancuso S; Tassone MT; Costa C; Russo A; Trecarichi EM; Cuda G; Costanzo FS; Palmieri C; Torti C
Int J Infect Dis; 2022 Nov; 124():55-64. PubMed ID: 36116671
[TBL] [Abstract][Full Text] [Related]
26. Emergence of E484K Mutation Following Bamlanivimab Monotherapy among High-Risk Patients Infected with the Alpha Variant of SARS-CoV-2.
Peiffer-Smadja N; Bridier-Nahmias A; Ferré VM; Charpentier C; Garé M; Rioux C; Allemand A; Lavallée P; Ghosn J; Kramer L; Descamps D; Yazdanpanah Y; Visseaux B
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452507
[TBL] [Abstract][Full Text] [Related]
27. Breadth and Durability of SARS-CoV-2-Specific T Cell Responses following Long-Term Recovery from COVID-19.
Dang TTT; Anzurez A; Nakayama-Hosoya K; Miki S; Yamashita K; de Souza M; Matano T; Kawana-Tachikawa A
Microbiol Spectr; 2023 Aug; 11(4):e0214323. PubMed ID: 37428088
[TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.
Steiner S; Schwarz T; Corman VM; Gebert L; Kleinschmidt MC; Wald A; Gläser S; Kruse JM; Zickler D; Peric A; Meisel C; Meyer T; Staudacher OL; Wittke K; Kedor C; Bauer S; Besher NA; Kalus U; Pruß A; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
Front Immunol; 2022; 13():840126. PubMed ID: 35359967
[TBL] [Abstract][Full Text] [Related]
29. SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients.
Ferré EMN; Schmitt MM; Ochoa S; Rosen LB; Shaw ER; Burbelo PD; Stoddard JL; Rampertaap S; DiMaggio T; Bergerson JRE; Rosenzweig SD; Notarangelo LD; Holland SM; Lionakis MS
Front Immunol; 2021; 12():720205. PubMed ID: 34504497
[TBL] [Abstract][Full Text] [Related]
30. Children and Adults With Mild COVID-19: Dynamics of the Memory T Cell Response up to 10 Months.
Kaaijk P; Pimentel VO; Emmelot ME; Poelen MCM; Cevirgel A; Schepp RM; den Hartog G; Reukers DFM; Beckers L; van Beek J; van Els CACM; Meijer A; Rots NY; de Wit J
Front Immunol; 2022; 13():817876. PubMed ID: 35197982
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive Treatment of Hematological Patients with SARS-CoV-2 Infection Including Anti-SARS-CoV-2 Monoclonal Antibodies: A Single-Center Experience Case Series.
Boeckel GR; Hölscher SD; Bürger C; Jacob T; Krekeler C; Shumilov E; Reicherts C; Bleckmann A; Lenz G; Vollenberg R; Tepasse PR
Curr Oncol; 2022 Mar; 29(4):2312-2325. PubMed ID: 35448162
[TBL] [Abstract][Full Text] [Related]
32. Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific T Cells and Antibodies in Coronavirus Disease 2019 (COVID-19) Protection: A Prospective Study.
Molodtsov IA; Kegeles E; Mitin AN; Mityaeva O; Musatova OE; Panova AE; Pashenkov MV; Peshkova IO; Alsalloum A; Asaad W; Budikhina AS; Deryabin AS; Dolzhikova IV; Filimonova IN; Gracheva AN; Ivanova OI; Kizilova A; Komogorova VV; Komova A; Kompantseva NI; Kucheryavykh E; Lagutkin DА; Lomakin YA; Maleeva AV; Maryukhnich EV; Mohammad A; Murugin VV; Murugina NE; Navoikova A; Nikonova MF; Ovchinnikova LA; Panarina Y; Pinegina NV; Potashnikova DM; Romanova EV; Saidova AA; Sakr N; Samoilova AG; Serdyuk Y; Shakirova NT; Sharova NI; Sheetikov SA; Shemetova AF; Shevkova LV; Shpektor AV; Trufanova A; Tvorogova AV; Ukrainskaya VM; Vinokurov AS; Vorobyeva DA; Zornikova KV; Efimov GA; Khaitov MR; Kofiadi IA; Komissarov AA; Logunov DY; Naigovzina NB; Rubtsov YP; Vasilyeva IA; Volchkov P; Vasilieva E
Clin Infect Dis; 2022 Aug; 75(1):e1-e9. PubMed ID: 35435222
[TBL] [Abstract][Full Text] [Related]
33. Bamlanivimab and Etesevimab administered in an outpatient setting for SARS-CoV-2 infection.
Bavaro DF; Diella L; Solimando AG; Cicco S; Buonamico E; Stasi C; Ciannarella M; Marrone M; Carpagnano F; Resta O; Carpagnano GE; Palmieri VO; Vacca A; Dell'Aera M; Dell'Erba A; Migliore G; Aricò M; Saracino A
Pathog Glob Health; 2022 Jul; 116(5):297-304. PubMed ID: 35138229
[TBL] [Abstract][Full Text] [Related]
34. Failure of bamlanivimab with selection of E484K mutation in an allogeneic stem cell transplant recipient with nosocomial SARS-CoV-2 infection.
Boussen I; Salmona M; Sicre De Fontbrune F; Xhaard A; De Castro N; Delaugerre C; Chaix ML; Molina JM
Antivir Ther; 2024 Feb; 29(1):13596535221097495. PubMed ID: 38353416
[TBL] [Abstract][Full Text] [Related]
35. Do we need bamlanivimab? Is etesevimab a key to treating Covid-19?
Doggrell SA
Expert Opin Biol Ther; 2021 Nov; 21(11):1359-1362. PubMed ID: 34555986
[TBL] [Abstract][Full Text] [Related]
36. A Comparison of SARS-COV-2 Neutralizing Antibody Therapies in High-Risk Patients with Mild to Moderate COVID-19 Disease at a Single Academic Hospital.
Farcy DA; Dalley MT; Miro G; Swalley P; Sherman D; Nash J; Jodoin K; Cubeddu LX; Zitek T; Goldszer R
J Emerg Med; 2022 Jan; 62(1):83-91. PubMed ID: 34489146
[TBL] [Abstract][Full Text] [Related]
37. The potential clinical utility of measuring severe acute respiratory syndrome coronavirus 2-specific T-cell responses.
Goletti D; Petrone L; Manissero D; Bertoletti A; Rao S; Ndunda N; Sette A; Nikolayevskyy V
Clin Microbiol Infect; 2021 Dec; 27(12):1784-1789. PubMed ID: 34256141
[TBL] [Abstract][Full Text] [Related]
38. Bamlanivimab use in mild-to-moderate COVID-19 disease: A matched cohort design.
Destache CJ; Aurit SJ; Schmidt D; Peet Erkes L; Tierney M; Vivekanandan R
Pharmacotherapy; 2021 Sep; 41(9):743-747. PubMed ID: 34328670
[TBL] [Abstract][Full Text] [Related]
39. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies.
Vellas C; Del Bello A; Debard A; Steinmeyer Z; Tribaudeau L; Ranger N; Jeanne N; Martin-Blondel G; Delobel P; Kamar N; Izopet J
Clin Microbiol Infect; 2022 Jan; 28(1):139.e5-139.e8. PubMed ID: 34537363
[TBL] [Abstract][Full Text] [Related]
40. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents.
Wolf J; Abzug MJ; Anosike BI; Vora SB; Waghmare A; Sue PK; Olivero RM; Oliveira CR; James SH; Morton TH; Maron GM; Young JL; Orscheln RC; Schwenk HT; Bio LL; Willis ZI; Lloyd EC; Hersh AL; Huskins CW; Soma VL; Ratner AJ; Hayes M; Downes K; Chiotos K; Grapentine SP; Wattier RL; Lamb GS; Zachariah P; Nakamura MM
J Pediatric Infect Dis Soc; 2022 May; 11(5):177-185. PubMed ID: 35107571
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
